Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylprednisolone Pulse Therapy Regimens for Graves' Ophthalmopathy
NCT06693856Enrolling by invitation
- Start
- Jan 2025
- Primary completion
- Jun 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised trial of methylprednisolone injection in Graves' ophthalmopathy (TED) (2 arms). Primary endpoint: Overall Response Rate at 24 weeks. Started Jan 2025; status: enrolling by invitation.
02
Drugs
methylprednisolone injection
03
Conditions
Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on NCT06693856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06693856.